---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000007"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:20:33.651905+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novocure's Optune Lua receives CE Mark for metastatic NSCLC treatment

## Summary
- CE Mark for Optune Lua in mNSCLC with immune checkpoint inhibitors or docetaxel after platinum progression.
- Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua) vs 9.9 months (control); primary endpoint met.
- Subgroup with immune checkpoint inhibitor: median OS 18.5 vs 10.8 months (P=0.03).
- Local registration initiated in Germany; launch expected in coming weeks. FDA approval received Oct 2024.
- Post-market study of TTFields with docetaxel required as condition; 180 patients, 12-month follow-up.

## SEC filing metadata
- accession: 0001645113-25-000007
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000007/0001645113-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000007/nvcr-20250422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000007
- JSON: https://secwatch.observer/filing/0001645113-25-000007.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.